Varex Imaging Corp (VREX) 2017 Q4 法說會逐字稿

Greetings, and welcome to the Varex Imaging Corporation Fourth Quarter Fiscal Year 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Howard Goldman, Director of Investor Relations. Please go ahead, sir.

Good afternoon and welcome to Varex Imaging Corporation's Earnings Conference Call for the 4th quarter and fiscal year 2017. With me today are Sunny Sanyal, our President and CEO; and Clarence Verhoef, our CFO.

To simplify our discussion, unless otherwise stated, all references to the quarter or year are fiscal quarters and fiscal years. Quarterly comparisons are for the 4th quarter of fiscal 2017 versus the 4th quarter of fiscal 2016, unless otherwise stated. Annual comparisons are for fiscal year 2017 versus fiscal year 2016 unless also otherwise stated. Comparable financial statements for fiscal year 2016 and the first quarter of fiscal year 2017 reflect operating results for the Imaging Components business of Varian Medical Systems prior to our separation, and include estimates of cost allocations for various corporate functions, interest expense and tax expense.

Additionally, financial statements for the 4th quarter and the last 5 months of fiscal year 2017 include operating results for the imaging business we acquired from PerkinElmer on May 1 of 2017. In addition, we supplement our consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles, or GAAP, with the use of adjusted or non-GAAP financial measures of certain elements of financial performance.

These adjusted measures are not presented in accordance with, nor are they a substitute for, GAAP financial measures. These adjusted measures include adjusted gross margin, adjusted operating earnings, adjusted operating earnings margin, adjusted net earnings and adjusted net earnings per diluted share. We provide a reconciliation of each adjusted financial measure to the most direct comparable GAAP financial measure in our earnings press release, which is posted on our website. We are unable to provide without unreasonable effort a reconciliation of adjusted net earnings to the corresponding GAAP measures on a forward-looking basis due to the potential significant variability and limited visibility of the excluded items discussed.

Please be advised that this discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Our use of words and phrases such as expects, intend, outlook, future, anticipate, will, could, believe, estimate, guidance and similar expressions are intended to identify those statements which represent our current judgment on future performance or other future matters. While we believe them to be reasonably based on information currently available to us, these are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Risks relating to our business are described in our 4th quarter earnings release and in our filings with the SEC. The information in this discussion speaks as of today's date and we assume no obligation to update or revise the forward-looking statements in these discussions because of new information, future events or otherwise. And now I'll turn the call over to Sunny.

Thank you, Howard. Hello, everyone, and good afternoon. Fiscal year 2017 was a transformational year for us. We successfully completed our spinoff from Varian to become a new publicly traded company, and we closed a major acquisition of the imaging business from PerkinElmer. We accomplished these actions while maintaining our focus on growing revenue and providing excellent customer service. Our strong performance in the 4th quarter and the fiscal year reinforces our belief that our emphasis and commitment to X-ray imaging components has enabled us to serve our customers better and provide greater value to our stockholders.

Let me start by highlighting a few financial results. A little later, Clarence will discuss our results in more detail. For fiscal year 2017, our revenues increased 13% to $698 million, with the Medical segment up 10% and the Industrial segment up 24% over the prior year. This growth reflects a 3% increase in revenues or $17 million from our organic business, and the addition of $61 million in revenues in the last 5 months of the year from the acquired imaging business. Revenues from this acquired imaging business increased 5% from the same 5-month period in prior year.

In our Medical segment, we experienced good growth from sales of our CT tubes, as well as our mammography, dental and surgery components. Sales of CT tubes are up for the year, driven by activity in Asia. As previously discussed, we expect demand for CTs in emerging markets, particularly China, to continue to grow. We're continuing to see evidence of that as local OEMs make progress towards introduction of new systems using our CT tubes, reinforcing our confidence in both the market opportunity and our competitive position.

Growth in dental and mammography applications was mainly due to continued adoption of new 3D imaging applications for dental implant procedures and tomosynthesis for mammography. The proliferation of these applications has been driven by improved performance and cost effectiveness of X-ray detectors, as well as technology advances in X-ray sources, which enables 3D imaging at lower dose, higher resolution and faster speed.

Our Industrial segment also performed well, mostly driven by sales of security products. During the year, we experienced the recovery and demand from our high-energy linear accelerators for both cargo screening and industrial inspection applications.

For airport security, we continue to work with our OEM customers to develop new applications. Several projects are focused on incorporating our X-ray tube technology into CT applications, which improve screening effectiveness for carry-on and checked baggage.

In addition, we now have a new platform for compact and lightw8 linear accelerators for mobile cargo screening and industrial nondestructive testing applications. We see these as future growth opportunities for us.

Now looking at the 4th quarter of the fiscal year 2017, our revenues increased 25% to $216 million. This growth reflects a 5% increase in revenues, or $9 million, from our organic business, and the addition of $35 million in revenues from the acquired imaging business. This was the largest quarter in our history, even without the contribution from the acquisition. We recovered from a soft third quarter, with revenues in the 4th quarter that were $46 million higher than the previous quarter.

During the 4th quarter, our sales team was very active and closed several new multiyear agreements for X-ray tubes, linear accelerators and digital detectors. Most of these have 3-year terms and they are collectively valued at approximately $200 million over the life of the agreements. We view this as a favorable shift in the way our customers want to work with us, compared to historical 1-year agreements.

I'm excited to report that the sales activity included an agreement with another local OEM customer in China for our CT tubes. Combining this new agreement with the one that we announced last quarter, we expect them to generate more than $100 million of incremental revenues over the respective 3-year lives of these agreements. We anticipate that the development work which we did in the past few years will result in additional agreements for our CT tubes, with local Chinese OEMs in the future.

Switching gears, I'm pleased to report that the integration of the acquired imaging business continues to move forward on schedule. Cross-selling is a key focus. Last quarter, we discussed meeting with senior executives of customers of the acquired imaging business. Since then, we've met with product and R&D teams to present our expanded portfolios beyond the detector-only business. We're having active discussions and negotiations with 2 major customers to supply our X-ray sources and our new subsystem package of an X-ray tube, generator, high-voltage cables and software. I'm optimistic that these cross-selling efforts will result in new commercial projects over time.

We have made a lot of progress at merging supply chain operations and qualifying new sources for certain critical materials, which is a key step towards achieving the anticipated cost savings we had outlined on our last call. Behind the scenes, we completed the first phase of computer systems integration with the successful migration of 3 sites onto the Varex computer ne2rk and ERP system. Overall, we believe we're on track to achieve our cost synergy goal of $5 million in fiscal year 2018.

Our digital detector business grew significantly during the fiscal year, with addition of the acquired imaging business. One of our long-term growth opportunities in this business is the ongoing conversion of analog film and CR-based imaging methods to digital detectors.

Let me give you a few market updates. Adoption of digital detectors is continuing due to new technologies as well as reimbursement changes. In the U.S., CMS has already reduced reimbursement for the use of film-based radiographic imaging systems by 20%. Further, beginning in January 2018, reimbursement for the use of CR-based imaging systems will be reduced by 7% and deepen to 10% in 2023.

In addition, the demand for digital detectors for surgical imaging systems is starting to accelerate. Approximately 8,000 mobile CR systems are sold each year around the world, which represents a significant opportunity for us.

With the addition of the acquired imaging business, we are now able to offer an expanded portfolio of both amorphous silicon and CMOS-based digital detectors for mobile C-arms.

In fiscal year 2017, we introduced more than a dozen new and updated medical products. At the end of November, we will once again be at the RSNA Conference in Chicago. This annual event is the largest of the 30 or so trade shows that we participate in around the world each year. We will be displaying some of our newest products and technologies at RSNA. More importantly, many of our OEM customers will be showcasing their next generation X-ray imaging systems that have our new technology inside. I'm proud to say that most of the X-ray imaging systems at RSNA are likely to have a Varex component inside.

Examples of our new technologies include integrated CT subsystem packages that would include a CT tube, generator, tube control unit, high-voltage connectors and heat exchanger. A high resolution, high performance, radiographic digital detector. A family of mammography detectors for value, mid-tier and high-end tomosynthesis applications. A series of collimators, from manual to fully motorized, for both radiographic and fluoroscopic applications. And an image acquisition workstation tailored to midsize OEMs for use with various fluoroscopic imaging applications.

Lastly, I'm pleased to report that during the 4th quarter, our Salt Lake City facility received LEED gold certification for the 150,000-square-foot expansion that was completed in 2016. As a large manufacturer, energy efficiency and sustainability are important to us and we feel strongly about using resources wisely. Over the past few years, we have completed dozens of projects that saved Varex more than 6 million kilowatt hours of energy each year at our Salt Lake City facility. This equates to a 21% annual energy reduction for us that has freed up enough electricity to power more than 7,000 homes.

With that, let me hand over the call to our CFO, Clarence Verhoef, to talk about our financial performance in greater detail.

Thanks, and hello, everyone. A year ago, Sunny and I had our first interaction with you on the Varian earnings call, and we were explaining the challenges of the prior 2 years and the status of the impending spinoff. We had optimism about the upcoming year and were also in the midst of negotiations for a very significant acquisition.

Now, a year later, I'm proud to say that we've returned to revenue growth, that our earnings exceeded expectations in 2017, and that our exceptional team has been expanded with the additional detector expertise from the acquired imaging business. Our guidance will reflect that we expect revenues to be nearly 30% higher in 2018 than in 2016.

Let me summarize the key financials for the 4th quarter and fiscal year, and then go through the outlook for 2018. This was the first full quarter of results for our acquired imaging business, and it has a large impact on the results. In the 4th quarter, it added $35 million of revenue. Including the results of the acquisition, our 4th quarter revenues were up 25% to $216 million, and the fiscal year revenues were up 13% to $698 million.

Medical segment revenues increased 22% in the 4th quarter to $164 million and included $24 million from the acquired imaging business. For the quarter, we had growth across all our product platforms, with particularly strong growth in X-ray tubes and software. Fiscal year revenues were up 10% to $557 million.

Industrial segment revenues for the 4th quarter increased 38% to $51 million and included $11 million from the acquired imaging business. Fiscal year revenues were up 24% to $141 million. We saw good results in the security market, which delivered double-digit growth this year.

For the 4th quarter, our gross margin was 36% compared to 40% in the prior year quarter. The adjusted gross margin was 38% compared to 41% a year ago. Gross margin rates improved for X-ray tubes, software and connect and control products. However, detector margin rate declined due to pricing pressures and a mix of lower margin products.

For the fiscal year, our gross margin was 36% compared to 40% in the prior year. Our fiscal year adjusted gross margin was 38% compared to 40% in the prior year. The improvement in the second half gross margin over the first half is encouraging, and we still expect our long-term gross margins to be in the range of 38% to 40%.

R&D expenses were $22 million or 10% of revenues in the quarter, which increased from $14 million or 8% in the year-ago quarter. For the year, R&D expenses were 9.6% of revenues compared to 8.6% in the prior year. This increase was due to higher prototype material costs, primarily for CT X-ray tube development projects, and also due to a higher R&D level of spending in the acquired imaging business.

Fourth quarter SG&A expenses increased to $29 million or 14% of revenues from $22 million or 13% of revenues in the prior year. Fourth quarter included $2 million of expenses from the acquired imaging business, as well as $4 million of acquisition and integration costs.

Depreciation and amortization totaled $27 million for the fiscal year, compared to $15 million a year ago.

Our operating earnings for the 4th quarter were $27 million, down from $33 million in the same quarter a year ago. Our operating margin rate was 12% in the 4th quarter, a decline from 19% in the year-ago quarter, reflecting the acquisition-related cost and the decrease in gross margin.

For the 4th quarter, our adjusted operating earnings were $35 million compared to $34 million in the prior year. The adjusted operating earnings margin was 16% compared to 20% in the prior year.

Fiscal year operating earnings margin was 12% compared to 18% in the prior year. Fiscal year adjusted operating earnings margin was 15% compared to 19% in the prior year. The decline in margin reflects the lower gross margin rate and the increased level of R&D investment for the year.

Interest expense in the 4th quarter was $6.5 million. Our effective tax rate for the 4th quarter was 18%, compared to 30% in the year-ago quarter. The lower rate was due to the utilization of foreign net operating losses that could not be used prior to our separation. For the fiscal year, our effective tax rate was 30% compared to 34% last year.

Net earnings for the 4th quarter were $15 million or $0.39 per diluted share. This compares to net earnings of $22 million or $0.58 per diluted share in the prior year. For the 4th quarter, adjusted net earnings were $22 million or $0.59 per diluted share compared to $23 million or $0.61 per diluted share in the prior year. Diluted shares outstanding were 38 million shares versus 37.7 million shares in the prior year.

Fiscal year net earnings were $52 million or $1.36 per diluted share compared to $69 million or $1.82 per diluted share. Fiscal year adjusted net earnings were $1.80 compared to $1.96 in the prior year.

Now turning to the balance sheet. We ended the 4th quarter with cash and cash equivalents of $83 million. During the quarter, we reduced debt by $16 million to $494 million.

Looking at our working capital, accounts receivable increased by $30 million during the quarter due to the high volume of invoicing. Days sales outstanding was 68 days compared to 66 days in the third quarter. Inventory decreased by $22 million during the quarter, with the higher shipments at the end of the fiscal year.

Guidance for the company's net earnings per diluted share is provided on an adjusted basis only. This adjusted financial measure is forward-looking, and the company is unable to provide a meaningful or accurate compilation of reconciling items to guidance for GAAP net earnings per diluted share due to the uncertainty of the amount and timing of the unusual items.

For fiscal year 2018, the company expects that revenues will grow by 13% to 14% over fiscal year 2017, including the additional revenues from a full year of the acquired imaging business. For fiscal year 2018, the company expects adjusted net earnings to be in a range of $1.78 to $1.88 per diluted share.

For fiscal year 2018, we expect to have adjusted gross margins of 38% to 38.5%, a tax rate of 33% to 34%, and interest expense of approximately $20 million to $22 million.

Adjusted net earnings for 2018 will include incremental stock-based compensation of about $3 million as we transition to a full year of our equity plan.

At this time, we'd like to open up the call for your questions.

(Operator Instructions) We have a question from Mr. Larry Solow, CJS Securities.

Just a couple questions on Q4 and then on the outlook. Can you discuss the adjusted gross margin by segment in the quarter? Was there a greater impact of charges on the Medical or on the Industrial side, or was that sort of equally balanced by (inaudible) revenue? And then as you look at 2018, where do you see those going by segment?

First of all, we don't actually do the adjusted gross margin at the segment level, we only do that at the total level. I would say, though, that what you see as the gross margin rates, just by doing the calculations on the P&L, you'll see that the Industrial has higher gross margins than the Medical, and that the amount of adjustments that happened to get it down to the adjustment number is relatively equal between the 2 or comparable to those. I mean, you can do it pro rata. It's a good indication.

Fair enough. And then just sticking to that, the Q4 on the expense side looked like R&D was a little bit above sort of where you guys have been tracking, and SG&A a little bit below? Is that fair to say? And then should we expect that to balance out a little bit as we look on to 2018?

Yes, I think you've got it exactly right. I do think that we had R&D come in at a little bit north of 10% of revenue in the quarter. And we've got some significant projects going on, particularly around CT. And when you get to the level where you're kind of at the tail end of these projects and you're introducing products to the market, there's a fair amount of prototype cost associated with that, so that's why we end up with a little bit higher cost on the R&D line.

I don't think that for looking into next year, it'll be at quite that level. Kind of more, maybe half a point lower, somewhere in that kind of range, so -- is probably a better indicator of where that is. And yes, you're right, SG&A as a percent of revenue is down, and some of that's tied to the high volume of revenue, right? I mean, so just as those costs are staying relatively the same level, but you've got higher revenues, you get the benefit of that, which is kind of our story all along, is that we want to be able to leverage SG&A with growth.

Right. And just on Perkin, it sounds like things haven't really changed, or your expectations. So is it fair to say revenue should be sort of flattish or at the run rate it's been for the last 5 months of this year? Just trying to figure out, back my way into what you think organic growth will be next year.

So I guess how I'd say that is that it is now being integrated into our business very much so, and so it basically falls into the same growth rates that we would be expecting to have in our core business.

Okay. So do you still think for 2018 it's sort of plus or minus sort of 3% on the healthcare side and mid-singles on the industrial side? Is that a good place to start for organic growth?

Yes, I think that gets you there, because I think you can work your way backwards into getting to that point by using the run rate of a full year of PerkinElmer and basing that or comparing that with the 13% to 14% total top-line growth that we've given guidance for.

And just last question, on the CT side. Is most of the growth coming from, looks like if I back my way into the 2 Chinese contracts that you've added, I don't know -- it's probably not going to be a linear 30 each year over the next 3 years, so I don't know what your contributions are in 2018. I imagine probably less than [the third]. But, question, that's part one. And then part 2, if you're getting that incremental growth from that, on the Toshiba contract side, is that actually coming in a little bit or are you actually getting year-over-year growth from outside of Asia on CT?

So I'll answer it a little bit differently, but I think it's going to give you the answer you're looking for, which is that fundamentally where we saw our growth happening in CT is in Asia. But you've got to remember that Toshiba's in Japan, and so that's a big piece of our business. And so, we had good performance in Asia all the way around, and that's a combination of the activities that happened in Japan, not only Toshiba but also a few other customers there. And then the growth that we've had happening in China.

And so, relative to those contracts, I think you're right. I mean, these things ramp up over time. And I can't even necessarily tell you exactly the amount of how much of the $100 million is in year 1 versus 2 versus 3, but just recognize that year 3 is going to be the highest of the 3.

Okay, and do those contracts, or at least the initial one you signed last quarter, did that contribute anything in Q4?

Yes, we've already been delivering on that contract. Not to a large amount, but I mean it is reflected in the fact that now we've gotten to the level where our business in China is not 10% of our revenue. So, I mean, that's a little bit of an indicator of what we've seen. And a year ago, it was at 8%, I believe.

The next question is from Paul Coster from JP Morgan.

I'm at risk of getting a little muddled here. So the $200 million of new multiyear orders that closed in the 4th quarter, that does not include the previously announced $100 million from China, or am I mistaken there?

It does not include the previously announced $75 million. We had an (inaudible) that we did last quarter for $75 million.

Yes, got it. Okay, thank you. And then the $200 million that did close in the 4th quarter, was it for new logos or expanded programs with existing customers?

It was a combination. So obviously what we booked in China were new product placements, but the rest were additional modalities, additional revenue streams, or new revenue streams. A combination of renewals and new revenue streams with existing customers.

I think the significance of what we mentioned was the fact that we're seeing an increasing trend towards multiyear contracts. Now, in the past few years, there was so much volatility and movement in the competitive landscape pricing that customers were hesitant to sign more than a 1-year contract, but we're seeing now they're willing to consider a 3-year contract. It's a move in the right direction for us.

The acquired business was in a modest decline kind of trajectory before you acquired it, and it seems to have turned around pretty quickly. How do you account for that?

We're optimistic that it'll grow at the rates that we're experiencing and that we're seeing, because they're playing in the same space that we are, using our same channels, and there's a healthy pipeline of new products, so we expect it to swing back into growth mode.

Well, you fixed it pretty quickly, is my sense. If you can give us some sense of what action you took?

Yes, I guess how I'd put it is there's a little bit where -- I'm not sure we can take all the credit for that, because I think it has to do also with the fact that they had a decline in the prior couple years tied to currency, just like we had some impact from currency. So to have the currency stabilize and in fact even move a little bit in the other direction is helpful from that perspective.

At the same time, they've introduced some new products that are now starting to go to market, and I think that's exciting as we look at where they're going with some of these new products. The introduction and the adoption of CMOS in a couple of different applications is one of the things that helps drive it, as well as a next generation radiographic detector that they have.

Got it. Last question. As you look at your customer base, what's the array of product innovation there? The new product cadence, is it constant or is it accelerating, and what's the implication for you?

I'd say you maybe could put it in 2 camps. In China, it's all new, and many new products are being brought out by our customers. And the rest of the world, that cadence is more or less consistent with what we've seen in the past on the Medical side. Industrial, I'd classify it the same way. There's no really significant change in the cadence.

We have a question from Mr. Scott Marx, Samlyn Capital.

Can you just run through the guidance again for the gross margin tax rate interest expense? I couldn't get all that.

So I'll go from the top on down, okay? So, revenue growth, 13% to 14%. EPS, $1.78 to $1.88. So an in-between, gross margins, 38% to 38.5%. Tax rate, 33% to 34%. Interest expense, $20 million to $22 million. And then I just wanted to make sure that people were aware that we have an incremental in our SG&A expense of about $3 million of stock-based comp. Those were kind of the highlights that I went through.

The next question is from John Koller, Oppenheimer + Close.

Quick question on the digital detector pricing pressure and margins. I'm wondering if you can talk a little bit about how you think about getting out in front of that on engineering (inaudible) out and if you have some sort of timeline to take advantage of Perkin's capabilities.

Let me start and Clarence, you can take it from there as well. So, a couple things. On the price erosion, there was a [bolus] of price erosion that occurred in the second half of 2015 and the first half of 2016. What we're feeling now in our revenues was the impact of the price erosion, which made its way into our product line, and I think we're lapping that now.

On an ongoing basis, we're not seeing that kind of price erosion. It's gone back to what I'd call its historical norms of mid to low single-digit price erosion. So we're used to that, and that's something we can keep up with and keep pace with through reductions or through reductions on our costs of goods, with supply chain actions, with projects that we run to reduce material costs. And at the same time, we have been consistently introducing new detector models that are lower in cost.

So at this point, our expectation is that the cost reduction actions that we're taking will keep up with the price erosion that'll occur, and it's occurring primarily in the lower -- the value segments and the radiographic segments. So it's returning to more of the historical norms that we're used to.

Maybe the one thing I'd add to that is that what we have impact of at various times is the mix of what we sell, because there is higher-end products that have a lot more technology and that just get higher gross margins and higher price. And then kind of the more fundamental systems and products have a basically little bit lower margin. So when we run into problems where we see the margin go down, it's more driven, a lot driven by the mix of what we sell, probably more than what you actually see from just actual price erosion itself.

(Operator Instructions) The next question is from Mr. Anthony Petrone, Jefferies.

Maybe just to start a little bit on the quarter, and then a couple on just the tender process over in China. On the quarter, just a little bit more on Medical organic growth. I know some of the issues raised last quarter, just the aftermarket business sort of impacted things there a bit. So maybe just an update on the CT tube aftermarket sales and how that played out in the 4th quarter, and then how do you see that trending into 2018?

I'll start with that one. So we saw, basically, aftermarket was stabilized, I guess, because we've seen several quarters in a row where it had declined previously. So even though for the overall year, it is a decline, the Q4 was stabilized from that perspective. So I'd say that it's still an area that we're watching closely, and a lot of it is dependent on kind of the large OEMs that we are providing replacement products for and what their strategies are in the market.

Okay, and then the tenders in total, so just to be clear, 275 inclusive of the 75 last quarter, but I think you were actively engaged in a number of tenders. So can you give an update on, looking ahead, how many OEM tender processes is the company actively involved in, and what do you think the win rate on those can be this year?

Yes, so let me clarify. These are not tenders. In China, we're engaged with I'd say the top 10 OEMs there, and these are -- for the last several years, we've been actively involved in engineering our components into their products. Now, as they get ready to bring these products to market, one of the last steps in the process is they submit for their Chinese FDA registration. It's around that time that we start asking them for a forecast, because the launch is then in sight. It's within a sort of 12-month window, so to say. And we sign pricing agreements and try to lock them into a pricing agreement for a 1- to 3-year period.

So that's what these agreements reflect. It's our customers maturing their R&D pipeline and getting to a point where they're getting ready to launch. And so, we announced one last quarter. There's another one that we signed, and we're confident that there are several more to go as this year, 2018, evolves.

Got it. And then just jumping over to Industrial, the underlying organic growth number jumped out. And so, just the moving parts there, was it more dental, was it more mammography, security, just the moving parts there? And then the last one for me would just be your outlook on M&A, whether that be in 2018 or beyond.

Okay. So on the Industrial, growth in Industrial came from both the, we call low energy and high energy segments, which is our -- it was a good, solid, strong performance across the board. However, in this quarter we saw, we were encouraged by the number of linear accelerators that we sold, and it was driven by a combination of both cargo and NDT. So it was balanced across the board. So we saw strength in Industrial, I'd say across the board.

In terms of our M&A going forward, we're absorbing PerkinElmer, and that's going very well and I'm very happy about that. We're back into the mode of looking at our pipeline. The business is settling down from the spin-related activities and our management team is regaining their bandwidth. We're going back towards what we've always done, which is we'll keep looking at the pipeline for adjacencies and those kinds of opportunities. And we'll keep doing that.

Ladies and gentlemen, we've reached the end of the question-and-answer session. I'd like to turn the call back to management for closing remarks. Please go ahead.

Thank you, everyone, for your questions and participating in our earnings conference call for the 4th quarter and fiscal year 2017. A replay of this quarterly teleconference will be available starting today through November 23, and could be accessed at the company's website or by calling 1-877-660-6853 from anywhere in the U.S., or 1-201-612-7415 from non-U.S. locations, and the password is 13672496.

And with that, goodbye.

This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.